Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

58.20 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,013,832
Open 58.20
Bid (Size) 62.11 (3)
Ask (Size) 62.14 (1)
Prev. Close 58.20
Today's Range 58.20 - 58.20
52wk Range 45.05 - 135.20
Shares Outstanding N/A
Dividend Yield 3.78%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Novo Nordisk Stock Jumps After-Hours On Wegovy Pill Breakthrough As Weight-Loss War With Eli Lilly Heats Up
The Danish drugmaker has already filed the once-daily pill with U.S. regulators, aiming for the first FDA-approved oral GLP-1 treatment for obesity. 
Via Stocktwits
Why Novo Nordisk Stock Popped Today
Novo Nordisk lost half its value over the past year. Is it cheap enough to buy now? 
Via The Motley Fool

Performance

YTD
-33.5%
-33.5%
1 Month
+8.3%
+8.3%
3 Month
-21.4%
-21.4%
6 Month
-26.3%
-26.3%
1 Year
-55.9%
-55.9%

More News

Read More
Eli Lilly Says Its Obesity Pill Topped Novo Nordisk’s Oral Drug In Late-Stage Diabetes Trial
Via Stocktwits
Class Action Filed Against Novo Nordisk A/S (NVO) Seeking Recovery for Investors - Contact Levi & Korsinsky
Via NewMediaWire
Topics Fraud Lawsuit
Class Action Filed Against Novo Nordisk A/S (NVO) Seeking Recovery for Investors - Contact Levi & Korsinsky
Via TheNewswire.com
Topics Fraud Lawsuit
US FDA Alleges Novo Nordisk’s Video On Weight-loss Drugs Featuring Oprah Winfrey Is ‘False Or Misleading’
Via Stocktwits
Novo Nordisk Says New Obesity Treatment Achieved 11.8% Body Weight Reduction In Late-stage Study
Via Stocktwits
2 High-Yield Dividend Stocks You'll Wish You Had Bought 10 Years From Now
Via The Motley Fool
Why Novo Nordisk Stock Popped Today
Via The Motley Fool
Novo Nordisk Navigates a GLP-1 Gold Rush: Soaring Obesity Drug Sales Clash with Revised Outlook Amidst Mounting Competition
Via MarketMinute
Topics Earnings Economy Intellectual Property
Hims & Hers Scrutinized For Marketing Its Product As Similar To Ozempic, Wegovy
Via Benzinga
Stock Of The Day: Is The Novo Nordisk Death Spiral Finally Over?
Via Benzinga
Wegovy's Next Step: Novo Nordisk Eyes Approval for Higher-Dose Treatment
Via Benzinga
3 Undervalued Healthcare Stocks to Buy Now While They're Cheap
Via The Motley Fool
Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 30, 2025 to Discuss Your Rights - NVO
Via NewMediaWire
Topics Fraud Lawsuit
Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 30, 2025 to Discuss Your Rights - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
Here Is My Top Stock Pick Among the Weight Loss Industry Leaders
Via The Motley Fool
What's Going On With Novo Nordisk Shares Monday?
Via Benzinga
Novo Nordisk's Rybelsus Now First Oral GLP-1 RA In Europe With Proven Heart Health Impact
Via Benzinga
Novo Nordisk's Weight-Loss Wonders Drive Q2 Growth Amidst Shifting Sands of Competition
Via MarketMinute
Topics Economy Intellectual Property
Novo Nordisk Faces Headwinds: Competitive Pressures and Compounded Drugs Force Lowered Outlook
Via MarketMinute
Topics Economy Intellectual Property Law Enforcement
Why Novo Nordisk Stock Popped Today
Via The Motley Fool
Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - NVO
Via NewMediaWire
Topics Fraud Lawsuit
Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
NOVO ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire

Frequently Asked Questions

Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 58.20
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 09/17/25 07:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.